Media Release: Analogue insulin as an essential medicine: the need for more evidence and lower prices

ACCISS Study members wrote a letter, published in The Lancet Diabetes and Endocrinology as the World Health Organisation Expert Committee considers putting analogue insulin on the Model List of Essential Medicines, highlighting how its addition could, in fact, reduce access to insulin in LMICs, and call for lower prices and more evidence | See the letter here

Media Release: Access a Major Obstacle for One in Two People Using Insulin to Manage Type 2 Diabetes

A paper published in The Lancet Diabetes and Endocrinology estimates that, between 2018 and 2030, the number of people with type 2 diabetes using insulin will rise to 79 million. But without improved availability and affordability, over half of those will face challenges in accessing this life-saving medicine | Download the Press Release

Media Release: Shocking Disparity Between Insulin Prices and Cost of Production

A study published on Tuesday 25 September, 2018 in BMJ Global Health shows that, in a global market dominated by just three multinational companies, people living with diabetes are paying far more than they should for life-saving insulin. | Download the Press Release

Media Release: Health Action International Commend Decision By World Health Organization Not To Include Long-Acting Analogue Insulins On The Essential Medicines List

Press Release | 6 June, 2017 | Download PDF

Statement to the 21st meeting of the WHO Expert Committee on Selection and Use of Essential Medicines

Presented by Dr. Marg Ewen on 27 March 2017 | Click here to download the full statement.

Comment from Health Action International to Expert Committee on the application to include long-acting analogue insulins in the WHO Model List of Essential Medicines

Submission to the Expert Committee from HAI

Insulin discounts lower price burden for Americans, but insulin still not affordable worldwide

AMSTERDAM— Researchers conducting a global study into the barriers to insulin access call on Eli Lilly, Novo Nordisk and Sanofi to lower prices for all types of insulin worldwide and for greater transparency of actual prices paid for insulin. Read more 

ACCISS Study Reveals Numerous Barriers Hindering Access to Insulin for Millions in Need

GENEVA—A number of barriers are impeding access to insulin around the world, according to new research published today by Health Action International, Geneva University Hospitals/University of Geneva and Boston University School of Public Health. Read more 

Listen: ACCISS Study Investigator, David Beran, Speaks to The Lancet D&E About Insulin Access

Coinciding with the release of the ACCISS Study’s new Review, ‘Constraints and Challenges in Access to Insulin: A Global Perspective‘, in The Lancet Diabetes & Endocrinology, co-author David Beran spoke with the journal about key issues affecting access to insulin. Read more

Innovative Global Study Launched to Improve Access to Insulin

AMSTERDAM—Health Action International (HAI) has launched an innovative global study, called Addressing the Challenges and Constraints of Insulin Sources and Supply (ACCISS), to identify the causes of poor availability and high insulin prices and develop policies and interventions to improve access to this life-saving medicine, particularly in the world’s most under-served regions. Read more

Insulin costs NHS five times more than it should 
The Times of London – September 25, 2018

Long-acting insulin price concerns challenge WHO proposal
InPharma Technologist – May 30, 2017

La fulgurante progression du diabète en Afrique – featuring David Beran
RTS – Radio – April 6, 2017

Diabète: les oubliés de l’insuline
Tribune de Geneve – March 4, 2016

Call for Action to Improve Global Access to Insulin
Medscape – February 08, 2016

Insulin Out of Reach for Millions Around the Globe
Medpage Today – February 6, 2016